Xilio Therapeutics, Inc. - XLO

Sector: Healthcare · Industry: Pharmaceutical Preparations
Website: No information yet · Social: No information yet

Company profile

Powered by TradingView

Quarter snapshot

Latest / Compare
Q1 2026 · Q4 2025
Value (USD)
Total reported value ($000)
$22.82M
QoQ value delta ($000)
-$2.594M (-10.21%)
Implied price effect (QoQ)
+820.55%
Shares
Total shares
3,875,173
QoQ shares delta
-35,852,642 (-90.25%)
Total shares held by funds (by quarter)

Market chart (XLO)

Powered by TradingView
Interactive chart by TradingView.

Top holders (Q1 2026)

Top 25 only Full list
Partial Q1 2026 data: 24 holders have filed so far. Prior holders are carried forward until their next 13F confirms a change.
Manager Value ($000) Shares % of 13F
Bain Capital Life Sciences Investors, LLC 5,584 664,021 0.5%
GILEAD SCIENCES, INC. 5,469 650,389 0.26%
Frazier Life Sciences Management, L.P. 3,553 422,505 0.09%
Sio Capital Management, LLC 1,282 152,464 0.18%
VANGUARD CAPITAL MANAGEMENT LLC 1,039 123,660 0.0%
Caligan Partners LP 942 112,128 0.06%
Merck & Co., Inc. 891 105,982 0.25%
VANGUARD GROUP INC 803 1,255,692 0.0%
Stonepine Capital Management, LLC 539 64,162 0.22%
MORGAN STANLEY 483 57,493 0.0%
RENAISSANCE TECHNOLOGIES LLC 416 49,566 0.0%
AJU IB Investment Co., Ltd. 401 47,695 1.31%
GEODE CAPITAL MANAGEMENT, LLC 312 37,197 0.0%
FMR LLC 307 36,558 0.0%
VANGUARD FIDUCIARY TRUST CO 239 28,475 0.0%
GSA CAPITAL PARTNERS LLP 143 16,946 0.01%
Velan Capital Investment Management LP 120 14,285 0.08%
Ghisallo Capital Management LLC 116 13,800 0.0%
STATE STREET CORP 111 13,311 0.0%
CWM, LLC 35 4,206 0.0%
UBS Group AG 33 4,038 0.0%
JPMORGAN CHASE & CO 1 240 0.0%
ROYAL BANK OF CANADA 1 91 0.0%
Vanguard Global Advisers, LLC 1 210 0.0%
Key FInancial Inc 0 59 0.0%